Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safet

Name: Phase 3 Topline: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safet
Start: 2030-05-01

May 1, 2030

Company: Abivax SA (ABVX)
Drug: moderately
Indication: Ulcerative Colitis

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safet — ABVX Phase 3 Readout | BioSniper